Hoth Therapeutics, Inc. , a patient-focused clinical-stage biopharmaceutical company, announced that it has received an official Filing Receipt from the United States Patent and Trademark Office (USPTO) for a new patent application related to the proprietary formulation of HT-001, the Company's lead clinical asset.

This newly filed application seeks to expand the Company's intellectual property portfolio surrounding HT-001 and builds upon Hoth's already approved patent for the compound. The formulation-specific filing is aimed at further protecting the unique composition and delivery method of HT-001, which is being developed as a novel topical treatment to alleviate dermatologic side effects commonly experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor therapy.

"The receipt of this Filing Receipt from the USPTO marks another critical milestone in the development of HT-001," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "Expanding our patent protection to include formulation-specific claims reinforces the strength of our IP position and our long-term commitment to patients and shareholders."

The USPTO Filing Receipt confirms that the patent application has been formally accepted and will proceed through the examination process. This development adds an important layer of protection as Hoth continues advancing HT-001 through clinical development.